Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Shanghai Zhimeng Biopharma describes potassium channel activators

Dec. 16, 2019

Blood-brain barrier disruption could be Alzheimer's target

Dec. 16, 2019

Phase II results for vasopressin V1B receptor antagonist TS-121 in MDD

Dec. 16, 2019

Biogen discontinues development of gosuranemab for progressive supranuclear palsy

Dec. 16, 2019

FDA grants accelerated approval to Vyondys 53 for DMD in patients amenable to skipping exon 53

Dec. 13, 2019

Study confirms target engagement with BTRX-335140 in healthy volunteers

Dec. 13, 2019

TDP-43-mediated splicing repression as a therapeutic target for ALS-FTD

Dec. 13, 2019

Phase I data presented for the novel M1 mAChR modulator VU-319

Dec. 13, 2019

Roche and Genentech identify SCN9A blockers

Dec. 12, 2019

NCKAP1 as a new therapeutic target in ALS

Dec. 12, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...